Safe use of tocilizumab in rheumatic patients with Kaposi's sarcoma

Dermatol Ther. 2022 Nov;35(11):e15797. doi: 10.1111/dth.15797. Epub 2022 Sep 13.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Humans
  • Sarcoma, Kaposi* / drug therapy

Substances

  • tocilizumab
  • Antibodies, Monoclonal, Humanized